Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Concetta Fargnoli

Showing results (261-270 of 284) with videos related to

Pageof 29
Sort By:
Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Journal of Clinical Medicine|February 26, 2025
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis)Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
The Journal of Dermatological Treatment|August 15, 2023
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 yearsCataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Nature Genetics|April 2, 2014
Rare missense variants in POT1 predispose to familial cutaneous malignant melanomaJianxin Shi, Xiaohong R Yang, Bari Ballew, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Pageof 29

Showing results (261-270 of 284) with videos related to

Sort By:
Pageof 29
Dermatology and Therapy|October 10, 2025
Effectiveness, Safety, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis Treated with Lebrikizumab: A 16-Week Nationwide Retrospective Cohort StudyGianluca Avallone, Andrea Bombelli, Luigi Gargiulo, et al.
Clinical and Experimental Dermatology|July 9, 2026
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter StudyMaddalena Napolitano, Giuseppe Lauletta, Marianna Cimmino, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Journal of Clinical Medicine|February 26, 2025
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients-IL PSO (Italian Landscape Psoriasis)Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Clinical and Experimental Dermatology|June 11, 2024
Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patientsSilvia Ferrucci, Simona Tavecchio, Carlo Alberto Maronese, et al.
The Journal of Dermatological Treatment|August 15, 2023
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 yearsCataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2020
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre studyOlga Nigro, Graziella Pinotti, Federica De Galitiis, et al.
Nature Genetics|April 2, 2014
Rare missense variants in POT1 predispose to familial cutaneous malignant melanomaJianxin Shi, Xiaohong R Yang, Bari Ballew, et al.
Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.
Pageof 29